Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4734693 | 0.79 | GABRA1 (0.34) | — | |
| SCHEMBL17028403 | 0.75 | ADRB2 (0.36) | ADRB2PDE2A | |
| SCHEMBL28297439 | 0.75 | ADRB2 (0.36) | ADRB2PDE2A | |
| SCHEMBL8638829 | 0.74 | ADRB2 (0.48) | ADRB2PDE2A | |
| SCHEMBL24008886 | 0.74 | ADRB2 (0.48) | ADRB2PDE2A | |
| SCHEMBL557913 | 0.74 | IDO1 (0.42) | ADRB2PDE2A | |
| SCHEMBL1728961 | 0.74 | IDO1 (0.42) | ADRB2PDE2A | |
| SCHEMBL1004099 | 0.74 | IDO1 (0.42) | ADRB2PDE2A | |
| SCHEMBL22624077 | 0.73 | — | — | |
| SCHEMBL20771993 | 0.73 | LOXL2 (0.44) | ADRB2PDE2AAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | ADRB2 95/4885PDE2A 992/4885AAK1 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.